Submit Release
News Search

There were 455 press releases posted in the last 24 hours and 442,705 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Merck Provides Update on Phase III Clinical Program for Preladenant, the Company’s Investigational Parkinson’s Disease Medicine

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image

By continuing to use this site, you agree to our Terms & Conditions, last updated on September 30, 2025.

We use cookies to enhance your experience. Learn more